本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease. In today's rapidly evolving market landscape, precise forecasting is essential for biopharmaceutical companies. Yet, traditional research methods often come with limitations that can lead to inaccurate estimations and costly consequences. Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population. The solution facilitates precise assessments, identification of niche populations and accurate predictions based on population insights. Ravindra Sharma, VP Product Management, Clarivate, said: "The launch of Epidemiology Intelligence marks a significant milestone for Clarivate in our ongoing commitment to deliver comprehensive and actionable solutions to life sciences and healthcare companies. Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform. The new solution enables them to deliver safe, effective and commercially successful treatments to patients faster." Epidemiology Intelligence accelerates data-driven decision-making across the drug development lifecycle. Clients can benchmark market forecasts, validate investments, pinpoint growth opportunities and utilize the solution to strategically position their products for success. To learn more about Epidemiology Intelligence, visit here. About Epidemiology Intelligence Epidemiology Intelligence is a new, unified Clarivate patient population offering that brings together our legacy Epidemiology and Incidence and Prevalence Database solutions, as well as claims-based population insights, on a single platform. This transformative solution offers user-friendly visualizations, easy data exports and a unique breadth and depth of patient population insights. Conduct thorough market assessment with comprehensive coverage across 1200+ diseases and procedures. Dive deep into expert disease-specific epidemiology analysis and 10 and 20-year forecasts across 220 indications and over 5000 patient populations. Leverage expanded patient segmentation and location granularity with insights sourced from Clarivate U.S. Real-World Data. About ClarivateClarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com Media Contact:Catherine DanielDirector External Communications, Life Sciences & Healthcarenewsroom@clarivate.com
HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company (KOSDAQ: 195940), today announced a licensing and partnership agreement for the development and commercialization of ecnoglutide injection (XW003), a novel GLP-1 analog for the treatment of type 2 diabetes, obesity and MASH, in South Korea. Under the terms of the agreement, Sciwind Biosciences will receive an upfront payment and will be eligible to receive additional development, regulatory, and commercial milestones of up to US$56 million, as well as up to double-digit royalties from future product sales. HK inno.N Corporation will receive the exclusive rights to develop and commercialize ecnoglutide in the Republic of Korea. Sciwind Biosciences retains the right to develop and commercialize ecnoglutide in all other global markets. "We are very pleased to enter into this partnership with HK inno.N, which brings together their strong expertise in pharmaceutical development and commercialization in South Korea with the innovative experience of Sciwind in discovering novel therapeutics for metabolic diseases," said Hai Pan, Ph.D., founder and Chief Executive Officer of Sciwind Biosciences. "GLP-1 analogs are a promising class of medications for a range of indications. Clinical trials of ecnoglutide have demonstrated strong treatment benefits for patients with type 2 diabetes and obesity, as well as satisfactory safety and tolerability." "As metabolic diseases are affecting millions of patients in South Korea, we are excited to partner with Sciwind to develop ecnoglutide for the treatment of type 2 diabetes, obesity, and MASH," said Dalwon Kwak, Chief Executive Officer of HK inno.N. "Ecnoglutide has demonstrated a strong and differentiated product profile in clinical studies and we look forward to working together with Sciwind to rapidly progress its development in South Korea. Based on our experience of successful development and commercialization for brand new gastroesophageal reflux disease drug, K-CAB, we aim to make ecnoglutide our next blockbuster drug of more than 100 billion won in Korea." About ecnoglutide (XW003) Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for MASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. XW003 has demonstrated treatment benefits for patients with type 2 diabetes and obesity and is safe and well tolerated in clinical studies. About Sciwind Biosciences Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic diseases. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog ecnoglutide (Phase 3), oral ecnoglutide tablet XW004 (Phase 1), and oral small molecule GLP-1 receptor agonist XW014 (Phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com About HK inno.N Corporation HK inno.N Corp.(KOSDAQ 195940) is a South Korean pharmaceutical company. HK inno.N Corp. started its business as the pharmaceutical division of CJ Cheil Jedang Corp. in 1984 and was acquired by Kolmar Korea Corp. in 2018. In 2020, the company changed its name to HK inno.N Corp.. HK inno.N Corp. operates prescription drugs, health foods, and cosmetics businesses with the mission of 'Creating a healthier world where customers can enjoy a better life'. HK inno.N Corp. has the ability to develop the 'K-CAB Tab., the 30th new drug in Korea, and foster it as a blockbuster new drug for gastroesophageal reflux disease. Based on these capabilities, HK inno.N Corp. is developing innovative new drugs in the fields of digestive diseases, autoimmunity, and cancer. In addition to pharmaceuticals, it is further enhancing the company's future value by expanding its business into beverages, health foods, and cosmetics, starting with 'CONDITION', Korea's leading brand of hangover relief. For more information, visit www.inno-n.com/eng
KARLSKOGA, Sweden, May 7, 2024 /PRNewswire/ -- Today, Cell Impact has entered into a main agreement with Japanese company F.C.C., which governs the continued collaboration between the two companies to secure business primarily in Japan, India, and China. Cell Impact has entered into a main agreement with Japanese company F.C.C., an agreement that governs the continued collaboration between the two companies to secure business primarily in Japan, India, and China. Based on Cell Impact Forming™, a unique and patented technology for shaping flow plates, the companies can address customers’ needs regarding design of flow plates and optimization of the production processes. The main agreement leverages the strengths of both Cell Impact and F.C.C., outlining their respective responsibilities in various phases of upcoming deals. "Leveraging our expertise and Cell Impact Forming™, our unique and patented technology for shaping flow plates, we take responsibility for the initial cooperation with the customer, design and optimization of the product and process in future deals. This means assisting the customer in optimizing pattern design and developing tools and fixtures for analysis and verification, tailored for production," says Daniel Vallin, interim CEO of Cell Impact. F.C.C. is a globally established supplier to the automotive industry. Some of the company's strengths are its size, infrastructure, and long-established networks within Automotive. "We are pleased to collaborate with a successful manufacturer that has such a well-established network of contacts, especially in Japan, India, and China, where there is demand for flow plates initially for fuel cells. The agreement strengthens our position vis-à-vis world-leading players in the automotive industry," says Daniel Vallin. The collaboration between F.C.C. and Cell Impact has evolved gradually since August 2022 when the companies jointly decided to install a demonstration line on-site in Hamamatsu, Japan. The purpose was to demonstrate the efficiency of Cell Impact's patented forming technology for potential customers in Japan and other parts of Asia. Earlier today, Cell Impact announced a leasing agreement that will allow the company, together with F.C.C., to continue demonstrating Cell Impact Forming to customers and other stakeholders in the automotive industry. For more information, please contact:Daniel VallinCEO and IR contact, Cell Impact AB (publ)+46730686620 or daniel.vallin@cellimpact.com About Cell Impact Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power. The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company's Certified Advisor (CA).
HANOI, Vietnam, May 7, 2024 /PRNewswire/ -- On May 4th, MINISO, the renowned global lifestyle brand, celebrated the grand opening of its first IP collection store with a colorful creative storefront in Vietnam, showcasing MINISO's commitment to bringing joy and creativity to shopping experiences worldwide. Situated in the heart of Hanoi, close to the city's iconic landmark Hoan Kiem Lake, this flagship MINISO store also marked the debut of the much-awaited BT21 collection in Vietnam. MINISO IP Collection Store on Dinh Tien Hoang Street Located on Dinh Tien Hoang Street with a view facing Hoan Kiem Lake, the store is positioned at a prime location that attracts both locals and tourists alike. This initiative marks MINISO's first offline consumer experience store themed around BT21 in Vietnam, addressing the high demand for authentic BT21 MD previously sought after by Vietnamese consumers. The launch featured beloved items such as 9-inch plush toys, memory foam neck pillows, headbands, double-wall plastic tumblers with straws, and light-up keychains from the BT21 collection. MINISO IP Collection Store in Hanoi, Vietnam This MINISO superstore delivers global trends straight to the doorsteps of consumers in Vietnam. Beyond BT21 merchandise, it also boasts several IP zones featuring fan-favorite characters such as Lots-o'-Huggin' Bear, We Bare Bears, Pokémon, Snoopy, Minions, Marie, Winnie-the-Pooh, and Barbie among others. This diverse offering underscores MINISO's strategy to cater to various consumer interests through collaborations with globally recognized brands. The grand opening was a spectacle of color and excitement, featuring performances by dance troupes and local singer Isaac, who engaged with fans and delivered an electrifying performance. Miss International Vietnam 2024, Huỳnh Thị Thanh Thủy, added to the excitement by attending the ribbon-cutting ceremony. The festivities further included colorful Rickshaws circling Hoan Kiem Lake and activities that drew crowds eager to participate. Singer Isaac Attends the Opening Ceremony The new store, featuring a colorful creative storefront, marks the latest addition to MINISO's expansion efforts in Vietnam. Earlier, MINISO introduced several themed stores such as a Barbie-themed outlet in Hanoi, a Ho Chi Minh City store showcasing the Disney Pixar Food Collection, and a unique three-story establishment situated on Nguyen Trai Street, in the heart of Ho Chi Minh City's bustling commercial district. Miss International Vietnam 2024 Huỳnh Thị Thanh Thủy Graces Grand Opening Currently, there are over 70 MINISO stores spread across nearly 30 provinces in Vietnam. With an established presence across major cities such as Hanoi, Ho Chi Minh City, Hai Phong, Da Nang, and more, MINISO aims to extend its reach throughout more provinces focusing on top-tier commercial locations. By offering more vibrant offerings customized to local tastes and preferences, the brand remains dedicated to making sure that everyone gets to partake in what has become more than just a shopping trip - it's a unique experience. Store Opening Day of MINISO IP Collection Store at Hanoi Ho Hoan Kiem Lake
ADEPIDYN® technology on track to be first of Syngenta's crop protection active ingredients to attain billion-dollar annual sales within eight years of commercialization Following registration approval in Great Britain, farmers in more than 55 countries now have access to this powerful fungicide Success reflects Syngenta's innovation leadership in fungicides and the SDHI mode of action, and in bringing to market products with strong sustainability attributes BASEL, SWITZERLAND - EQS Newswire - 7 May 2024 - Syngenta Group, one of the world's largest agricultural technology companies, is extending its leadership in fungicides with the success of its patented ADEPIDYN® technology (trademark for active ingredient: pydiflumetofen). Following its recent registration in Great Britain, farmers in more than 55 countries globally are now able to access this powerful fungicide, with strong sales across continents reflecting farmer demand for effective control of a broad range of crop diseases. The company is on track to achieve one billion US dollars in sales of products containing ADEPIDYN® technology, marking the first time its active ingredient achieves this milestone in only eight years. Female farmer inspecting soyabean crops in field for sclerotinia (sclerotinia sclerotiorum) damage "ADEPIDYN® technology is a game-changer for modern agriculture and enables farmers to grow crops more sustainably," said Ioana Tudor, Global Head of Marketing at Syngenta Crop Protection. "It represents a significant milestone in our efforts to secure high yields with low impact to the planet and is exciting because of its high levels of consistency and effectiveness. We're very proud that our innovation is delivering such impact." Worldwide, farmers lose an estimated 10-23 percent of their crops to fungal diseases each year. An additional 10-20 percent is lost post-harvest. In the top five most important calorie crops – rice, wheat, corn, soybeans and potatoes – fungal infections have been estimated to cause yield losses that could feed at least 600 million people every day for a year. ADEPIDYN® technology offers a new solution that effectively fights fusarium head blight in wheat, which produces mycotoxins that contaminate harvests and threaten human and animal health. In addition, it offers a step-change in performance against a wide spectrum of other important diseases, such as septoria in wheat and net blotch in barley. ADEPIDYN® technology is registered in more than 100 crops including corn, soybean, peanuts, vegetables, potatoes, grapes, tomatoes and fruit crops. ADEPIDYN® technology embodies Syngenta's commitment to sustainable innovation, core to its new Group-wide sustainability priorities announced in April. The effectiveness and long-lasting activity of the technology enable low use rates and potentially fewer sprays especially in leaf spot diseases, while safeguarding beneficial organisms. It is also an important tool for resistance management. The technology works by inhibiting the activity of an enzyme that is essential for fungal respiration, starving the fungi from the energy they need to survive. It is designed to adhere to the plant surface and to penetrate rapidly through the leaf surface – creating a reservoir of active ingredient in the waxy layer of the plant tissue that enables even distribution and long-lasting protection as the plant grows. The technology further highlights Syngenta's success with the SDHI (Succinate dehydrogenase inhibitor) mode of action and the company's ability to effectively design active ingredients that address various farmer challenges. Following its first SDHI seed treatment sedaxane, Syngenta launched its SDHI fungicide isopyrazam which transformed farmers' ability to control sheath blight in rice, and later SOLATENOL® technology to protect crops against septoria and rusts. In Brazil, SOLATENOL® technology is today regarded as crucial in farmers' fight against soybean pod anomaly – a new fungal disease which spread within just three years to 12 states across the country since it was first identified. Beyond innovation in research and development, Syngenta's success is underpinned by its commitment to invest in cutting-edge manufacturing operations. Strong global demand has fueled investments aimed at increasing the efficiency of manufacturing of ADEPIDYN® technology. These set the foundation for the production of a growing portfolio of formulations containing ADEPIDYN® technology that target specific grower needs in different markets. The latest Syngenta innovation in the SDHI family is TYMIRIUM® technology, which was launched globally in 2022. In addition to protecting crops against key fungal diseases, TYMIRIUM® technology provides broad-spectrum protection against plant-parasitic nematodes that reduce global crop yield by an estimated 12 percent a year. Hashtag: #SyngentaThe issuer is solely responsible for the content of this announcement.About Syngenta GroupSyngenta Group is one of the world's biggest agricultural technology companies, with roots going back more than 250 years. With around 60,000 employees, operating in more than 100 countries, the company strives to transform agriculture with science-driven, technological innovations to deliver high productivity and high-quality food while fighting climate change and restoring nature. Syngenta Group works with farmers and partners to deliver four Sustainability Priorities: Higher Yields, Lower Impact; Regenerate Soil and Nature; Improve Rural Prosperity; and Sustainable Operations. The priorities are underpinned by regenerative agriculture practices to nurture and restore soil health, protect the climate and biodiversity, and enhance farm productivity and profitability. Syngenta Group, which is registered in Shanghai, China, and has its management headquarters in Switzerland, draws strength from its four business units: Syngenta Crop Protection, headquartered in Switzerland; Syngenta Seeds, headquartered in the United States; ADAMA®, headquartered in Israel; and Syngenta Group China. Together, these businesses provide industry-leading ways to serve customers around the world. For Syngenta Group photos and videos, please visit the Syngenta Group Media Library. Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR ("legitimate interest"). However, if you do not wish to receive further information about Syngenta Group, just send us a brief informal message and we will no longer process your details for this purpose. You can also find further details in our privacy statement. Cautionary Statement Regarding Forward-Looking Statements This document may contain forward-looking statements, which can be identified by terminology such as "expect," "would," "will," "potential," "plans," "prospects," "estimated," "aiming," "on track" and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta Group, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or grain prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta Group assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22. The goal is to raise critical awareness to prevent brain disease in all corners of the globe. The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day, on Monday, July 22. The goal is to raise critical awareness to prevent brain disease in all corners of the globe. "When we discuss brain health and prevention, we're safeguarding our blueprint for the future. It's not merely about reacting; it's about actively cultivating a culture of prevention for neurological diseases," said Prof. Wolfgang Grisold, President of WFN. "Our dedication to preventing neurological disorders is the cornerstone of our resilience for tomorrow." While there are no definitive cures for many neurological disorders, understanding and addressing risk factors can significantly alleviate this burden. A 2021 Global Burden of Disease Study revealed that over 3.40 billion individuals suffered declines in nervous system health, resulting in 11.1 million deaths attributed to related conditions. The study's findings encompass a range of neurological conditions, including stroke, Alzheimer's disease, other dementias, epilepsy, multiple sclerosis, Parkinson's disease, encephalitis, meningitis, and idiopathic intellectual disability. The study found that interventions such as reducing lead exposures, smoking cessation and managing glucose levels, could all yield substantial results in reducing the disease burden, in addition to lifestyle modifications like sleep, stress, diet and exercise. This underscores significant public health ramifications and the urgent need for awareness around preventive measures, making WBD 2024 an essential global health initiative based on five key points. Neurological disorders are preventable through early detection and effective management. Global education on prevention for brain health is imperative. Socioeconomic status or geographic location should not be barriers to prevention. Healthcare professionals, researchers, and policymakers play pivotal roles in addressing the global neurological needs. Recognizing brain health as a fundamental human right is at the core of our mission. "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair. "Through advocacy and policy changes, our collective voices will spark a worldwide movement for better preventive healthcare and pave the way for a brighter, healthier tomorrow." The WFN is honored to be joined in this initiative by representatives of the World Health Organization (WHO) Brain Health Unit as Guests of Honor for WBD 2024. WHO's presence underscores the importance of the Intersectoral Global Action Plan on epilepsy and other neurological disorders (IGAP), and its implementation worldwide. "As we approach World Brain Day 2024, let's come together to support brain health and prevention. Beyond just words, it's about taking meaningful action," says David Dodick, MD, Emeritus Professor of Neurology at Mayo Clinic and World Brain Day Co-Chair. "Together, we're shaping a future where prevention isn't just a concept but a way of life, ensuring that the generations to come inherit a world that prioritizes neurological disorders." The WBD 2024 committee is formed by representatives from each of the WFN Regional Neurological Associations: American Academy of Neurology (AAN) African Academy of Neurology (AFAN) Asian and Oceanian Association of Neurology (AOAN) European Academy of Neurology (EAN) Pan-American Federation of Neurological Societies (PAFNS) Pan Arab Union of Neurological Societies (PAUNS) Established by the WFN in 2014, World Brain Day continues to serve as a catalyst for public awareness on various neurological health topics each year. Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention. Visit wfneurology.org/world-brain-day-2024 for more information on how to join WBD. Individuals, societies and countries are encouraged to host their own activities and amplify their voices on social media using hashtags such as #WorldBrainDay, #WBD2024, and #BrainHealthandPrevention. About the World Federation of Neurology With support from its 124 national neurological Member Societies, the World Federation of Neurology fosters quality neurology and brain health worldwide by promoting neurological education and training, with an emphasis on under-resourced areas of the world. As a non-state actor in official relations, WFN supports the World Health Organization (WHO) efforts to give everyone an equal chance to live a healthy life. With Member Societies around the globe, WFN unites the world's neurologists to ensure quality neurology and advocate for people to have better brain health. Learn more about the World Federation of Neurology at wfneurology.org. Media Contact:Ryan Pollock, Yakkety Yakryan@yakketyyak.com
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
